Table 2: Psychopathology and clinical improvement measures at baseline, week 4 (end of Phase I) and week 8 (end of Phase II).

Measure, mean (SD)Total sample 𝑁 = 6 3 Fast responders * 𝑁 = 3 7 Slow responders * 𝑁 = 2 6

BPRS totalBaseline54.8 (9.2)55.1 (9.5)54.4 (8.9)
Week 441.4 (9.8)a35.9 (5.0)a49.2 (9.6)a
Week 839.1 (9.3)b,c35.7 (6.9)c43.9 (10.3)b,c

BPRS psychotic subscaleBaseline14.6 (2.9)14.3 (2.9)15.0 (2.8)
Week 49.9 (4.0)a7.3 (1.4)a13.7 (3.4)
Week 88.6 (3.5)b,c7.4 (2.6)c10.4 (3.9)b,c

BPRS negative symptoms subscaleBaseline6.3 (2.2)6.1 (2.2)6.6 (2.1)
Week 45.7 (1.7)a5.3 (1.4)6.2 (2.0)
Week 85.7 (1.7)c5.1 (1.2)c6.5 (1.9)

CGI-SBaseline4.5 (0.7)4.5 (0.8)4.5 (0.7)
Week 43.2 (1.1)a2.5 (0.6)a4.2 (0.8)a
Week 82.8 (1.1)b,c2.5 (1.0)c3.3 (1.1)b,c

QLSBaseline58.8 (20.1)57.9 (20.9)60.0 (19.3)
Week 468.3 (19.1)a75.1 (18.0)a58.5 (16.3)
Week 867.9 (20.8)c74.8 (20.0)c58.1 (18.1)

*Responder status determined after 4 weeks of risperidone at a dose of 2 mg/day.
Week 8 scores are on an LOCF basis for all measures.
aSignificant change from baseline to week 4, 𝑃 . 0 5 .
bSignificant change from week 4 to week 8, 𝑃 . 0 5 .
cSignificant change from baseline to week 8, 𝑃 . 0 5 .
BPRS: the Brief Psychiatric Rating Scale, CGI-S: Clinical Global Impression Severity Scale, QLS: Quality of Life Scale.